Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Cronos Australia Ltd. ( (AU:VIT) ) is now available.
Vitura Health Limited announced the appointment of Michael Sapountzis as its new Company Secretary, replacing Tom Howitt, who will remain as Chief Financial Officer until January 12, 2026. This leadership change aligns with Vitura’s operational priorities as it continues to advance its presence in the digital healthcare and medicinal cannabis markets. The move strengthens governance and administrative functions, positioning the company for future growth in its integrated healthcare systems.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
More about Cronos Australia Ltd.
Vitura Health Limited is an Australian-based diversified digital health company, listed on the ASX, operating various platforms and subsidiaries focused on medicinal cannabis distribution, telehealth services, and psychedelic therapies. Through its flagship Canview platform, the company provides an integrated healthcare ecosystem facilitating electronic prescriptions and seamless connections between prescribers, pharmacies, and patients. Its other ventures include telehealth services like Doctors on Demand and partnerships in distributing innovative products, such as MDMA and psilocybin for therapeutic use.
Average Trading Volume: 273,300
Technical Sentiment Signal: Sell
Current Market Cap: A$39.76M
See more data about VIT stock on TipRanks’ Stock Analysis page.